Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Obesity Surgery
Erschienen in: Obesity Surgery 6/2021

13.04.2021 | Review

Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis

verfasst von: Miller Barreto de Brito e Silva, Francisco Tustumi, Antonio Afonso de Miranda Neto, Anna Carolina Batista Dantas, Marco Aurélio Santo, Ivan Cecconello

Erschienen in: Obesity Surgery | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

The effects of bariatric procedures on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) remain unclear. A systematic review and meta-analysis was performed to compare the impact of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on NAFLD/NASH. Patients submitted to RYGB presented significant reduction of steatohepatitis (RD: 0.53; 95% CI 0.33 to 0.74) and fibrosis (RD: 0.26; 95% CI 0.14 to 0.37). SG caused a significant reduction of steatohepatitis (RD: 0.42; 95% CI 0.27 to 0.57), but not of fibrosis (RD: 0.20; 95% CI −0.00 to 0.39). The NAFLD Activity Score was significantly improved after both procedures, as well as biochemical tests. No difference was found between RYGB and SG regarding the histopathological outcomes. SG and RYGB are equivalently effective for treating NAFLD/NASH.

Graphical Abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
National Academies of Sciences, Engineering, and Medicine. Current status and response to the global obesity pandemic: proceedings of a workshop: National Academies Press; 2019.
2.
Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA, et al. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism. 2016;65(8):1196–207.PubMedCrossRef
3.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.PubMedCrossRef
4.
Udelsman BV, Corey KE, Lindvall C, et al. Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery. Surg Obes Relat Dis. 2019;15(6):843–9.PubMedCrossRef
5.
Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):162–8.PubMedCrossRef
6.
Ong JP, Younossi ZM. Nonalcoholic fatty liver disease (NAFLD) two decades later: are we smarter about its natural history? Am J Gastroenterol. 2003;98(9):1915–7.PubMedCrossRef
7.
Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132–8.PubMedCrossRef
8.
Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98(9):2042–7.PubMedCrossRef
9.
Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649–59.PubMedCrossRef
10.
Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–33.PubMedCrossRef
11.
Courcoulas AP, King WC, Belle SH, et al. Seven-year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) study. JAMA Surg. 2018;153(5):427–34.PubMedCrossRef
12.
Burza MA, Romeo S, Kotronen A, et al. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLoS One. 2013;8(3):e60495.PubMedPubMedCentralCrossRef
13.
Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–11.PubMedCrossRef
14.
Aromataris E, Munn Z. Joanna Briggs Institute reviewer’s manual, vol. 299: The Joanna Briggs Institute; 2017.
15.
GRADEpro GD. GRADEpro GDT: GRADEpro guideline development tool [software]. McMaster University, 2015 (developed by Evidence Prime, Inc.).
16.
Abdennour M, Reggio S, Le Naour G, et al. Association of adipose tissue and liver fibrosis with tissue stiffness in morbid obesity: links with diabetes and BMI loss after gastric bypass. J Clin Endocrinol Metab. 2014;99(3):898–907.PubMedCrossRef
17.
Aksoy EK, Göktaş Z, Albuz Ö, et al. Effects of sleeve gastrectomy on liver enzymes, non-alcoholic fatty liver disease-related fibrosis and steatosis scores in morbidly obese patients: first year follow-up. J Lab Med. 2019;43(2):115–22.CrossRef
18.
Aldoheyan T, Hassanain M, Al-Mulhim A, et al. The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc. 2017;31(3):1142–7.PubMedCrossRef
19.
Alsina ME, Ruiz-Tovar J, Bernabeu A. Evolution of liver steatosis quantified by MR imaging and MR spectroscopy, in morbidly obese patients undergoing sleeve gastrectomy: short-term outcomes. Obes Surg. 2017;27(7):1724–8.PubMedCrossRef
20.
Barker KB, Palekar NA, Bowers SP, et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol. 2006;101(2):368–73.PubMedCrossRef
21.
Batman B, Altun H, Simsek B, et al. The effect of laparoscopic sleeve gastrectomy on nonalcoholic fatty liver disease. Surg Laparosc Endosc Percutan Tech. 2019;29(6):509–12.PubMedCrossRef
22.
Berry MA, Urrutia L, Lamoza P, et al. Sleeve gastrectomy outcomes in patients with BMI between 30 and 35–3 years of follow-up. Obes Surg. 2018;28(3):649–55.PubMedCrossRef
23.
Billeter AT, Senft J, Gotthardt D, et al. Combined non-alcoholic fatty liver disease and type 2 diabetes mellitus: sleeve gastrectomy or gastric bypass?—a controlled matched pair study of 34 patients. Obes Surg. 2016;26(8):1867–74.PubMedCrossRef
24.
Cabré N, Luciano-Mateo F, Fernández-Arroyo S, et al. Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. Metabolism. 2019;99:81–9.PubMedCrossRef
25.
Caiazzo R, Lassailly G, Leteurtre E, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg. 2014;260(5):893–9.PubMedCrossRef
26.
Cherla DV, Rodriguez NA, Vangoitsenhoven R, et al. Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease. Surg Endosc. 2020;34(5):2266–72.PubMedCrossRef
27.
Clark JM, Alkhuraishi AR, Solga SF, et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res. 2005;13(7):1180–6.PubMedCrossRef
28.
Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg. 2006;16(5):607–11.PubMedCrossRef
29.
de Almeida SR, Rocha PR, Sanches MD, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg. 2006;16(3):270–8.PubMedCrossRef
30.
Del Genio F, Del Genio G, De Sio I, et al. Noninvasive evaluation of abdominal fat and liver changes following progressive weight loss in severely obese patients treated with laparoscopic gastric bypass. Obes Surg. 2009;19(12):1664–71.PubMedCrossRef
31.
Endo Y, Ohta M, Tada K, et al. Improvement of non-alcoholic fatty liver disease after laparoscopic sleeve gastrectomy in Japanese obese patients. Ann Gastroenterol Surg. 2019;3(3):285–90.PubMedPubMedCentralCrossRef
32.
Esquivel CM, Garcia M, Armando L, et al. Laparoscopic sleeve gastrectomy resolves NAFLD: another formal indication for bariatric surgery? Obes Surg. 2018;28(12):4022–33.PubMedCrossRef
33.
Franzini M, Musetti V, Guarino D, et al. γ-Glutamyltransferase fractions in obese subjects with type 2 diabetes: relation to insulin sensitivity and effects of bariatric surgery. Obes Surg. 2018;28(5):1363–71.PubMedCrossRef
34.
Froylich D, Corcelles R, Daigle C, et al. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016;12(1):127–31.PubMedCrossRef
35.
Furuya Jr CK, De Oliveira CP, De Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol. 2007;22(4):510–4.PubMedCrossRef
36.
Jimenez LS, Chaim FH, Chaim FD, et al. Impact of weight regain on the evolution of non-alcoholic fatty liver disease after Roux-en-Y gastric bypass: a 3-year follow-up. Obes Surg. 2018;28(10):3131–5.PubMedCrossRef
37.
Johansson HE, Wåhlén A, Aldenbäck E, et al. Platelet counts and liver enzymes after gastric bypass surgery. Obes Surg. 2018;28(6):1526–31.PubMedCrossRef
38.
Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wroblewska B, et al. Liver function in patients with nonalcoholic fatty liver disease randomized to Roux-en-Y gastric bypass versus sleeve gastrectomy: a secondary analysis of a randomized clinical trial. Ann Surg. 2017;266(5):738–45.PubMedCrossRef
39.
Karcz WK, Krawczykowski D, Küsters S, et al. Influence of sleeve gastrectomy on NASH and type 2 diabetes mellitus. J Obes. 2011;1:2011.
40.
Klein S, Mittendorfer B, Eagon JC, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology. 2006;130(6):1564–72.PubMedCrossRef
41.
Koh ZJ, Salgaonkar HP, Lee WJ, et al. Improvement in non-alcoholic fatty liver disease score correlates with weight loss in obese patients undergoing laparoscopic sleeve gastrectomy: a two-centre study from an Asian cohort. Obes Surg. 2019;29(3):862–8.PubMedCrossRef
42.
Kruschitz R, Luger M, Kienbacher C, et al. The effect of Roux-en-Y vs. omega-loop gastric bypass on liver, metabolic parameters, and weight loss. Obes Surg. 2016;26(9):2204–12.PubMedPubMedCentralCrossRef
43.
Liu X, Lazenby AJ, Clements RH, et al. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg. 2007;17(4):486–92.PubMedCrossRef
44.
Manco M, Mosca A, De Peppo F, et al. The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis. J Pediatr. 2017;180:31–7.PubMedCrossRef
45.
Mazzini GS, Khoraki J, Dozmorov M, et al. Concomitant PPARα and FXR activation as a putative mechanism of NASH improvement after gastric bypass surgery: a GEO datasets analysis. J Gastrointest Surg. 2019;23(1):51–7.PubMedCrossRef
46.
Moretto M, Kupski C, Da Silva VD, et al. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22(7):1044–9.PubMedCrossRef
47.
Motamedi MA, Khalaj A, Mahdavi M, et al. Longitudinal comparison of the effect of gastric bypass to sleeve gastrectomy on liver function in a bariatric cohort: Tehran Obesity Treatment Study (TOTS). Obes Surg. 2019;29(2):511–8.PubMedCrossRef
48.
Nascimento TM, Alves-Junior A, Nunes MA, et al. Comparison of hepatic profile in pre and postoperative of bariatric surgery: private vs public network. Arq Bras Cir Dig. 2015;28(4):274–7.PubMedPubMedCentralCrossRef
49.
Nobili V, Carpino G, De Peppo F, et al. Laparoscopic sleeve gastrectomy improves nonalcoholic fatty liver disease–related liver damage in adolescents by reshaping cellular interactions and hepatic adipocytokine production. J Pediatr. 2018;194:100–8.PubMedCrossRef
50.
Parker BM, Wu J, You J, et al. Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery. BMC Obes. 2017;4(1):32.PubMedPubMedCentralCrossRef
51.
Rega-Kaun G, Ritzel D, Kaun C, et al. Changes of circulating extracellular vesicles from the liver after Roux-en-Y Bariatric surgery. Int J Mol Sci. 2019;20(9):2153.PubMedCentralCrossRef
52.
Ruiz-Tovar J, Alsina ME, Alpera MR, et al. Improvement of nonalcoholic fatty liver disease in morbidly obese patients after sleeve gastrectomy: association of ultrasonographic findings with lipid profile and liver enzymes. Acta Chir Belg. 2017;117(6):363–9.PubMedCrossRef
53.
Salgado Júnior W, de Mattos Donadelli CA, dos Santos JS, et al. Influence of Roux-en-Y gastric bypass on the hepatocellular function and bile flow of obese patients assessed by scintigraphy with DISIDA. Obes Surg. 2016;26(11):2718–23.PubMedCrossRef
54.
Salman MA, Salman AA, Abdelsalam A, et al. Laparoscopic sleeve gastrectomy on the horizon as a promising treatment modality for NAFLD. Obes Surg. 2020;30(1):87–95.PubMedCrossRef
55.
Schneck AS, Anty R, Patouraux S, et al. Roux-en Y gastric bypass results in long-term remission of hepatocyte apoptosis and hepatic histological features of non-alcoholic steatohepatitis. Front Physiol. 2016;7:344.PubMedPubMedCentralCrossRef
56.
Schwenger KJ, Fischer SE, Jackson T, et al. In nonalcoholic fatty liver disease, Roux-en-Y gastric bypass improves liver histology while persistent disease is associated with lower improvements in waist circumference and glycemic control. Surg Obes Relat Dis. 2018;14(9):1233–9.PubMedCrossRef
57.
Silva LGDO, Manso JEF, Silva RARND, et al. Relationship of the nutritional status of vitamin a and the regression of hepatic steatosis after Roux-en-Y gastric bypass surgery for treatment of class III obesity. Arq Bras Cir Dig. 2012;25(4):250–6.PubMedCrossRef
58.
Tai CM, Huang CK, Hwang JC, et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg. 2012;22(7):1016–21.PubMedCrossRef
59.
Vargas V, Allende H, Lecube A, et al. Surgically induced weight loss by gastric bypass improves nonalcoholic fatty liver disease in morbid obese patients. World J Hepatol. 2012;4(12):382–8.PubMedPubMedCentralCrossRef
60.
von Schönfels W, Beckmann JH, Ahrens M, et al. Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score). Surg Obes Relat Dis. 2018;14(10):1607–16.CrossRef
61.
Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68(1):349–60.PubMedCrossRef
62.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.PubMedCrossRef
63.
Lee Y, Doumouras AG, Yu J, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040–60.PubMedCrossRef
64.
Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. Surg Obes Relat Dis. 2019;15(12):2123–30.PubMedCrossRef
65.
Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. In: Mayo Clinic Proceedings, vol. 90, No. 9: Elsevier; 2015. p 1233-1246.
66.
Ledoux S, Sami O, Calabrese D, et al. Gastric bypass specifically impairs liver parameters as compared with sleeve gastrectomy, independently of evolution of metabolic disorders. Surg Obes Relat Dis. 2019;15(2):220–6.PubMedCrossRef
Metadaten
Titel
Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis
verfasst von
Miller Barreto de Brito e Silva
Francisco Tustumi
Antonio Afonso de Miranda Neto
Anna Carolina Batista Dantas
Marco Aurélio Santo
Ivan Cecconello
Publikationsdatum
13.04.2021
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 6/2021
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-021-05412-y

Weitere Artikel der Ausgabe 6/2021

Obesity Surgery 6/2021 Zur Ausgabe

Original Contributions

Role of Robotic Surgery in Complex Revisional Bariatric Procedures

Original Contributions

Predictors of Postprandial Hypoglycemia After Gastric Bypass Surgery: a Retrospective Case-Control Study

Original Contributions

Bariatric-Metabolic Surgery Utilisation in Patients With and Without Diabetes: Data from the IFSO Global Registry 2015–2018

Original Contributions

Executive Functioning in Extreme Obesity: Contributions from Metabolic Status, Medical Comorbidities, and Psychiatric Factors

Brief Communication

Malnutrition and Alcohol in Patients Presenting with Severe Complications of Cirrhosis After Laparoscopic Bariatric Surgery

Original Contributions

Evaluating the Pharmacoeconomic Impact of Nutrient Supplementation Post-operatively on Patients Receiving Roux-Y Gastric Bypass vs. Biliopancreatic Diversion with Duodenal Switch

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise